Is there a role for the neoadjuvant use of CDK 4/6 inhibitors with endocrine therapy in patients with well differentiated and/or invasive lobular histology who desire breast conservation?
The use of neoadjuvant CDK 4/6 inhibitors is not standard of care, but there are clinical trials looking at this question and patients who are chemotherapy adverse are asking about this option.
Answer from: Medical Oncologist at Academic Institution
The role of neoadjuvant CDK4/6 inhibitors has been explored in multiple phase 2 trials including the neoMONARCH and PALLET trials. The data from these studies suggest that abemaciclib and palbociclib are active in ER+ early stage breast cancers by causing a more complete arrest of tumor cell prolife...
Sign in or Register to read more